nuButyrate™ 60 capsules nuBioAge

Butyrate prodrug, tributyrin, is proven to overcome the pharmacokinetic drawbacks of butyrate supplementation. Butyrate can epigenetically regulate gene expression. nuButyrate has the only regulatory compliant tributyrin on the market clinically substantiated to be bioavailable in the colon and to show improvement in boosting butyrate-producing bacteria. Butyrate has been shown to neutralize reactive oxygen species by the overexpression of glutathione peroxidase, causing the inhibition of NF-kB, leading to the activation of antioxidant enzymes and impairing inflammatory genes. nuButyrate is crucial to immune, gut, and metabolic health. Ingredients • Tributyrin (as CoreBiome®): 500 mg Recommended Use Take 2 capsules daily. Helping support digestive and gastrointestinal healththrough impacting gene expression, Tributyrin is the onlyform to be clinically substantiated bioavailability in thecolon. It supports immune health by supporting tightjunctures in the intestinal lining normalizing inflammatoryresponses in the gastrointestinal tract. Butyrate prodrug Tributyrin is proven toovercome the pharmacokinetic drawbacks ofbutyrate supplementation while eliminatingbad smell and taste. Cellular Pathways The overexpression of GPx causes the blocking of theNF-kB cascade, resulting in the attenuation of theinflammatory response by impairing the expression ofNF-kB inflammatory genes.Butyrate induces maturation and expansion of colonicregulatory T cellsPPARy, strongly expressed in the colon, controls the energyproduction required for microbiome homeostasis throughfatty acid oxidation. Why this matters: 3 days of Abx administered by oral gavage resulted in anearly complete loss of bacterial groups. Despite outgrowth ofseveral resistant organisms, cecal contents from abx-treatedmice lost the ability to produce SCFAs from inulin and lost HIFexpression, both of which are restored by butyrate administration.Butyrate is a potent activator of AMPK in colonic cell lines.*Kelly, C. Crosstalk between Microbiota-Derived Short-Chain Fatty Acids and Intestinal EpithelialHIF Augments Tissue BarrierFunction. Cell Host Microbe. 2015; 17(5): 662–671 Clinical StudiesnuButyrate™ Results Butyrate prodrug Tributyrin is proven to overcome the pharmacokentic drawbacks of butyrate supplementation while eliminating bad smell and taste.  It has been clinically substantiated bioavailability in the colon. * who performed the study? •    Faecalibacterium prausnitzii increased 41% over placebo•    Anaerostipes increased 67% over placebo•    Both bacteria are butyrate producers and their benefits are associated with butyrate production (healthy microbiome, immunity, healthy inflammatory response, etc.) Tributyrin (as CoreBiome®)  •     Is the #1 selling SCFA on the market•    Has clinically substantiated bioavailability in the colon•    In a 48-hour study using a gastrointestinal model [and that was repeated in a four-week study], CoreBiome® limited IL6, TNF-alpha and measurements of epithelial function through TEER (transepithelial electrical resistance), suggesting that it may support gut barrier function•     Is the ONLY SCFA with marketable claims Synergy with Larazotide, Guttides (BPC-157 + KPV): Critical component of GI protocols including Guttides (BPC-157 + KPV), Larazotide and low dose pentosan polysulfate. Larazotide + nuButyrate™ Larazotide protects the gut by improving and repairing tight junctions providing gut permeability protection. Larazotide improves the structure and integrity of the gut while nubutyrate works on creating the optimal environment through immune and inflammation modulation.  Guttides + nuButyrate™The combination of gut health peptides  BPC-157 and KPV improve inflammation and mucosal barrier integrity. nuButyrate is commonly used in conjunction to further improve the GI inflammatory state.